MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform

Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ($30.5 million CAD) for year ended December 31, 2020 NEW YORK, March 30, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31, 2020.

Source